European Union - English - EMA (European Medicines Agency)

valneva sweden ab - recombinant cholera toxin b subunit, vibrio cholerae 01 - cholera; immunization - vaccines - dukoral is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children from 2 years of age who will be visiting endemic/epidemic areas.the use of dukoral should be determined on the basis of official recommendations taking into consideration the variability of epidemiology and the risk of contracting disease in different geographical areas and travelling conditions.dukoral should not replace standard protective measures. in the event of diarrhoea measures of rehydration should be instituted.

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmaq as - infectious pancreatic necrosis virus, inactivated; listonella anguillarum serotype o2a; al 104; listonella anguillarum serotype o1; al 112; aeromonas salmonicida subsp. salmonicida, al 2017; moritella viscosa, al 266; vibrio salmonicida al 1134 - emulsion for injection - . - infectious pancreatic necrosis (ipn) virus + aeromonas + moritella + vibrio

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - recombinant cholera toxin b subunit 1mg; vibrio cholerae inaba 48 classical biotype 31250 million organisms (heat inactivated); vibrio cholerae inaba 6973 el tor biotype 31250 million organisms (formalin inactivated); vibrio cholerae ogawa 50 classical biotype 62500 million organisms (equal parts heat inactivated and formalin inactivated) - oral suspension - active: recombinant cholera toxin b subunit 1mg vibrio cholerae inaba 48 classical biotype 31250 million organisms (heat inactivated) vibrio cholerae inaba 6973 el tor biotype 31250 million organisms (formalin inactivated) vibrio cholerae ogawa 50 classical biotype 62500 million organisms (equal parts heat inactivated and formalin inactivated) excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection citric acid raspberry flavour 52383 ap0551 saccharin sodium sodium bicarbonate sodium carbonate sodium citrate dihydrate citric acid raspberry flavour 52383 ap0551 saccharin sodium sodium bicarbonate sodium carbonate sodium citrate - active immunisation of adults and children from two years of age, who will be visiting areas with an ongoing or anticipated epidemic or who will be spending an extended period of time in areas in which cholera infection is a risk. the vaccine should be considered for foreign aid workers and others intending to visit or spend an extended period of time in areas endemic or epidemic for cholera.

United States - English - NLM (National Library of Medicine)

the wellness center - horseradish (unii: 8ds6g120hj) (horseradish - unii:8ds6g120hj), toxoplasma gondii (unii: bmv90jf469) (toxoplasma gondii - unii:bmv90jf469), vibrio cholerae (unii: 4m0784008h) (vibrio cholerae - unii:4m0784008h), candida albicans (unii: 4d7g21hdbc) (candida albicans - unii:4d7g21hdbc), trichinella spiralis (unii: 2pyi6d7hcq) (trichinella spiralis - unii:2pyi6d7hcq), taraxacum officinale (unii: 39981fm375) (taraxacum officinale - unii:39981fm375), plasmodium malariae (unii: ar76cst9i2) (plasmodium mala - allergies, distention of abdomen, edema, constipation, diarrhea, intestinal dysbiosis, flu-like symptoms, skin rash, ulcers, boils, fever, vomiting, immune system, intestinal hemorrhaging.  allergies, distention of abdomen, edema, constipation, diarrhea, intestinal dysbiosis, flu-like symptoms, skin rash, ulcers, boils, fever, vomiting, immune system, intestinal hemorrhaging.

United States - English - NLM (National Library of Medicine)

emergent travel health inc. - vibrio cholerae cvd 103-hgr strain live antigen (unii: v9g528e9e0) (vibrio cholerae cvd 103-hgr strain live antigen - unii:v9g528e9e0) - vaxchora is a vaccine indicated for active immunization against disease caused by vibrio cholerae serogroup o1 in persons 2 through 64 years of age traveling to cholera-affected areas. the effectiveness of vaxchora has not been established in persons living in cholera-affected areas. the effectiveness of vaxchora has not been established in persons who have pre-existing immunity due to previous exposure to v. cholerae or receipt of a cholera vaccine. vaxchora has not been shown to protect against disease caused by v. cholerae serogroup o139 or other non-o1 serogroups. do not use in persons who have a history of severe allergic reaction (e.g., anaphylaxis) to any ingredient of vaxchora or to a previous dose of any cholera vaccine [see description (11)]. risk summary vaxchora is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. clinical considerations disease-associated maternal and/or embryo/fetal risk maternal cholera disease is associated with adverse pregnancy outcomes including fetal death. fetal/neonatal adverse reactions the vaccine strain may be shed in the stool of the vaccinated mother for at least 7 days, with a potential for transmission of the vaccine strain from mother to infant during vaginal delivery. risk summary vaxchora is not absorbed systemically by the mother following oral administration, and breastfeeding is not expected to result in exposure of the child to vaxchora. the safety and effectiveness of vaxchora have not been established in children younger than 2 years of age. the safety and effectiveness of vaxchora have not been established in adults 65 years of age or older. the safety and effectiveness of vaxchora have not been established in immunocompromised individuals. the immunologic response to vaxchora may be diminished in immunocompromised individuals [see drug interactions (7.3)] .

Singapore - English - HSA (Health Sciences Authority)

biomerieux singapore pte. ltd. - microbiology - chromid vibrio agar is a selective chromogenic medium for the isolation of most vibrio species from human specimens (stools, rectal swabs). this medium enables the presumptive identification of v. cholerae and v. parahaemolyticus which are responsible for severe intestinal illnesses.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - vibriosis - campylobacter foetus - unknown - vibriosis - campylobacter foetus vaccine active 0.0 - active constituent

Zimbabwe - English - Medicines Control Authority

sanofi-aventis south africa (pty) ltd - vibrio cholerae - suspension - 21000iu

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - formalin; campylobacter fetus venerealis biotype intermedius subt1; campylobacter fetus (vibro fetus) (refer aliases) - parenteral liquid/solution/suspension - formalin ungrouped active 2.0 ul/ml; campylobacter fetus venerealis biotype intermedius subt1 vaccine-microbial active 0.0 p; campylobacter fetus (vibro fetus) (refer aliases) vaccine-microbial active 0.0 q.s - immunotherapy - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - bovine venereal campylobacteriosis (bvc) | bovine vibriosis

United Kingdom - English - VMD (Veterinary Medicines Directorate)

msd animal health uk limited - aeromonas salmonicida subsp. salmonicida, infectious pancreatic necrosis virus, listonella anguillarum, moritella viscosa, vibrio salmonicida - emulsion for injection - inactivated viral and bacterial vaccine - atlantic salmon